<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="219">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 24, 2013</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01498328</url>
  </required_header>
  <id_info>
    <org_study_id>CDX110-06</org_study_id>
    <nct_id>NCT01498328</nct_id>
  </id_info>
  <brief_title>A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma</brief_title>
  <acronym>ReACT</acronym>
  <official_title>A Phase II Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celldex Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celldex Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to find out whether adding an experimental vaccine
      called rindopepimut (also known as CDX-110) to the commonly used drug bevacizumab can
      improve progression free survival (slowing the growth of tumors) of patients with relapsed
      EGFRvIII positive glioblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase II study will enroll patients into three groups. Group 1 are patients who have
      never been treated with bevacizumab. These patients will be randomly assigned to receive
      either rindopepimut/GM-CSF or KLH, each along with bevacizumab. Treatment assignment for
      Group 1 will be blinded. Group 2 and Group 2C patients are those who are refractory to
      bevacizumab (experienced recurrence or progression of glioblastoma while on bevacizumab or
      within 2 months of discontinuing bevacizumab). These patients will all receive
      rindopepimut/GM-CSF along with bevacizumab. Patients will be treated until disease
      progression or intolerance and all patients will be followed for survival. Patients may be
      treated with other therapies that are not part of the study after discontinuing treatment
      with the study vaccine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2011</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Groups 1 and 2: Progression-free survival rate</measure>
    <time_frame>6 months post-Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the antitumor activity of rindopepimut in adult patients with relapsed glioblastoma, as measured by the progression-free survival rate at 6 months post-Day 1 (PFS 6).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Group 2C: Objective Response Rate</measure>
    <time_frame>Every 8 weeks from Day 1 through progression or initiation of other anti-cancer therapy</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate the anti-tumor activity of rindopepimut in adult patients with relapsed glioblastoma, as measured by the objective response rate (ORR) for patients with measurable disease at study entry.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Until 28 days or initiation of other anti-cancer treatment, whichever is first</time_frame>
    <safety_issue>No</safety_issue>
    <description>Safety and tolerability will be evaluated by comparing the treatment regimens in regards to vital sign measurements, physical and neurological examinations, adverse events reporting, and Karnofsky performance status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor activity</measure>
    <time_frame>During treatment and every 8 weeks through follow up</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluated by comparing the treatment regimens for anti-tumor activity, including objective response rate, overall progression free survival (PFS), and overall survival (OS) for Groups 1 and 2; and PFS6, overall PFS, and OS for Group 2C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EGFRvIII-specific immune response</measure>
    <time_frame>Several times during the first month of treatment and then approximately every 8 weeks until treatment is stopped.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Characterize the EGFRvIII specific immune response to rindopepimut.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Glioblastoma</condition>
  <condition>Small Cell Glioblastoma</condition>
  <condition>Giant Cell Glioblastoma</condition>
  <condition>Gliosarcoma</condition>
  <condition>Glioblastoma With Oligodendroglial Component</condition>
  <condition>Recurrent Glioblastoma</condition>
  <condition>Relapsed Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>About half of the patients who have never received treatment with bevacizumab will receive rindopepimut/GM-CSF in a blinded fashion in combination with bevacizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>About half of the patients who have never received treatment with bevacizumab will receive KLH in a blinded fashion in combination with bevacizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 and 2C: Refractory to Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with progressive disease while currently on or within two months after discontinuing bevacizumab will be administered rindopepimut/GM-CSF while continuing (or restarting if they had stopped bevacizumab).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>A vascular endothelial growth factor (VEGF)-specific humanized monoclonal antibody angiogenesis inhibitor.  Infusions of 10 mg/kg of bevacizumab will begin on day 1 and will be administered every two weeks until progression of disease or intolerance during the treatment period.</description>
    <arm_group_label>Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut.</arm_group_label>
    <arm_group_label>Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control</arm_group_label>
    <arm_group_label>Group 2 and 2C: Refractory to Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rindopepimut (CDX-110) with GM-CSF</intervention_name>
    <description>Rindopepimut/GM-CSF will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance.  Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM-CSF.</description>
    <arm_group_label>Group 1a: Bevacizumab Naïve with Bevacizumab + rindopepimut.</arm_group_label>
    <arm_group_label>Group 2 and 2C: Refractory to Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KLH</intervention_name>
    <description>KLH will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 100 mcg of KLH.</description>
    <arm_group_label>Group 1b: Bevacizumab Naïve with Bevacizumab + KLH control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Among other criteria, patients must meet the following conditions to be eligible for the
        study:

          1. Age ≥18 years of age.

          2. Histologic diagnosis of glioblastoma (WHO Grade IV).

          3. First or second relapse of de novo glioblastoma or first diagnosis or first relapse
             of secondary glioblastoma .

          4. Previous treatment must include surgery, conventional radiation therapy and
             temozolomide (TMZ).

          5. Screening MRI must be obtained at least 4 weeks after any salvage surgery, and at
             least 12 weeks after radiation therapy.

          6. KPS of ≥ 70%.

          7. If applicable, systemic corticosteroid therapy must be at a dose of ≤ 4 mg of
             dexamethasone or equivalent per day during the week prior to Day 1.

          8. Evaluable disease in Groups 1 and 2; measurable disease in Group 2C

          9. Life expectancy &gt; 12 weeks.

         10. Patients in Group 2 and 2C must have had disease progression while receiving
             bevacizumab or within 2 months of treatment with bevacizumab.

        Exclusion Criteria:

        Among other criteria, patients who meet the following conditions are NOT eligible for the
        study:

          1. Subjects unable to undergo an MRI with contrast.

          2. History, presence, or suspicion of metastatic disease

          3. Prior receipt of vaccination against EGFRvIII.

          4. Any known contraindications to receipt of study drugs, including known allergy or
             hypersensitivity to keyhole limpet hemocyanin (KLH), GM-CSF (sargramostim; LEUKINE®),
             polysorbate 80 or yeast derived products, or a history of anaphylactic reactions to
             shellfish proteins.

          5. Use of non-protein based investigational therapy within 14 days prior to Day 1 or use
             of antibody-based investigational therapy within 28 days prior to Day 1.

          6. Clinically significant increased intracranial pressure (e.g., impending herniation),
             uncontrolled seizures, or requirement for immediate palliative treatment

          7. Evidence of recent hemorrhage on screening MRI of the brain

          8. Evidence of current drug or alcohol abuse.

          9. Patients in Group 1 must not have received prior treatment with bevacizumab.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Celldex Therapeutics</last_name>
    <email>Info@celldextherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thiru B Pillay, RN</last_name>
      <phone>205-934-1813</phone>
      <email>thiru@uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shirley Gibbs</last_name>
      <phone>205-975-0447</phone>
      <email>sgibbs@uab.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Louis B Nabors, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center / Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea E Ralph, RN</last_name>
      <email>andrea.ralph@dignityhealth.org</email>
    </contact>
    <investigator>
      <last_name>Lynn S Ashby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California (USC) Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aida Lozada, MA</last_name>
      <phone>323-865-3980</phone>
      <email>lozada@usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sandy Leong, RN</last_name>
      <phone>323-442-7532</phone>
      <email>sandyleo@usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rose K Lai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Irvine Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Siwak, Ph.D</last_name>
      <phone>714-456-8549</phone>
      <email>csiwak@uci.edu</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Bota, M.D., Ph.D</last_name>
      <phone>714-456-7214</phone>
    </contact_backup>
    <investigator>
      <last_name>Daniela Bota, M.D., Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thelma Munoz</last_name>
      <phone>415-353-2523</phone>
      <email>Munozt@neurosurg.ucsf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jane Rabbitt, RN</last_name>
      <phone>415-353-2652</phone>
    </contact_backup>
    <investigator>
      <last_name>Nicholas Butowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute, Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie N Bertrand</last_name>
      <phone>650-723-4467</phone>
      <email>sophieb@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cathy Recht, RN</last_name>
      <phone>650-723-6095</phone>
    </contact_backup>
    <investigator>
      <last_name>Gordon Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado, Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Robischon, RN, BSN</last_name>
      <phone>720-848-0661</phone>
      <email>Monica.robischon@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Denise Damek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Atlanta Cancer Care</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Asea</last_name>
      <phone>770-777-1315</phone>
      <email>jasea@atlantacancercare.com</email>
    </contact>
    <contact_backup>
      <last_name>Julie F Carney, RN, BSN</last_name>
      <phone>770-777-1315</phone>
      <email>jcarney@atlantacancercare.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ronald G Steis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Amidei, RN PhD</last_name>
      <phone>773-834-0323</phone>
      <email>camidei1@bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Crista Brawley, PhD</last_name>
      <phone>1-773-702-0316</phone>
    </contact_backup>
    <investigator>
      <last_name>Maciej Lesniak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Begley, R.N. , B.S.</last_name>
      <phone>312-563-2713</phone>
      <email>Amanda_Begley@Rush.edu</email>
    </contact>
    <contact_backup>
      <last_name>Suzanne Matney, R.N.</last_name>
      <phone>312-942-2388</phone>
    </contact_backup>
    <investigator>
      <last_name>Nina Paleologos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore University Health System</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Merrell, MD</last_name>
      <phone>847-570-2025</phone>
      <email>NeuroOncResearch@northshore.org</email>
    </contact>
    <contact_backup>
      <last_name>Pat Lada, RN</last_name>
      <phone>847-570-2025</phone>
      <email>NeuroOncResearch@northshore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ryan Merrell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David A Reardon, MD</last_name>
      <phone>617-632-2166</phone>
      <email>David_Reardon@DFCI.Harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Debra LaFrankie, RN, OCN</last_name>
      <phone>617-632-6327</phone>
    </contact_backup>
    <investigator>
      <last_name>David A Reardon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larry Junck, MD</last_name>
      <phone>734-936-7910</phone>
      <email>ljunck@umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>University of Michigan Cancer Answer Line</last_name>
      <phone>1-800-865-1125</phone>
      <email>canceranswerline@umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Larry Junck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sparrow Cancer Center</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicki Gilreath, RN, OCN</last_name>
      <phone>517-364-2811</phone>
      <email>Vicki.Gilreath@sparrow.org</email>
    </contact>
    <contact_backup>
      <last_name>Harsha Trivedi, PhD, RN</last_name>
      <phone>517-364-3712</phone>
    </contact_backup>
    <investigator>
      <last_name>Gordan Srkalovic, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Ochsner</last_name>
      <phone>314-286-2585</phone>
      <email>lochsner@dom.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>David Tran, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S. Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Dent Neurologic Institute</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226,</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olga Olga, B.S., CCRC</last_name>
      <phone>716-558-5670</phone>
      <email>oananina@dentinstitute.com</email>
    </contact>
    <contact_backup>
      <last_name>Kathleen Mogensen, M.S., ANP-C</last_name>
      <phone>716-558-5658</phone>
    </contact_backup>
    <investigator>
      <last_name>Laszlo Mechtler, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Long Island Brain Tumor Center at Neurology Surgery, P.C.</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. Kimberly Prabhu, MA, CCRP</last_name>
      <phone>516-478-0010</phone>
      <email>kprabhu@nspc.com</email>
    </contact>
    <contact_backup>
      <last_name>Kerry McConie, RN, OCN</last_name>
      <phone>516-478-0010</phone>
      <email>kmcconie@nspc.com</email>
    </contact_backup>
    <investigator>
      <last_name>J. Paul Duic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Serventi, PA-C</last_name>
      <phone>585-276-3971</phone>
      <email>jennifer_serventi@urmc.rochester.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nimish Mohile, MD</last_name>
      <phone>585-275-5863</phone>
    </contact_backup>
    <investigator>
      <last_name>Nimish Mohile, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Preston Robert Tisch Brain Tumor Center; Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annick DesJardins, MD</last_name>
      <phone>919-681-3824</phone>
    </contact>
    <contact_backup>
      <last_name>Susan Boulton, RN, BSN</last_name>
      <phone>919-668-0896</phone>
      <email>boult001@mc.duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Annick DesJardins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer MacLean, BS, RN, OCN</last_name>
      <phone>336-713-3539</phone>
      <email>jemaclea@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Glenn Lesser, MD</last_name>
      <phone>336-713-5440</phone>
      <email>glesser@wakehealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Glenn Lesser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Cancer Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>University of Cincinnati Cancer Institute</last_name>
      <phone>513-584-7698</phone>
    </contact>
    <investigator>
      <last_name>Rekha Chaudhary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Sloan, MD</last_name>
      <phone>216-844-6054</phone>
      <email>andrew.sloan@uhhospitals.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Peereboom, MD</last_name>
      <phone>216-445-6068</phone>
      <email>Peerebd@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Cathy Brewer, RN</last_name>
      <phone>216-444-7937</phone>
    </contact_backup>
    <investigator>
      <last_name>David Peereboom, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Legacy Research Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Staat, RN</last_name>
      <phone>503-413-8330</phone>
      <email>sstaat@lhs.org</email>
    </contact>
    <contact_backup>
      <last_name>Amy Reiter, RN</last_name>
      <phone>503-413-7094</phone>
      <email>areiter@lhs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jefferson Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa D. Pritchett or Eileen Maloney-Wilensky, MSN,RN, MHA and MSN, CRNP</last_name>
      <phone>215-615-4597</phone>
      <email>lisa.pritchett@uphs.penn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Suzanne Frangos, RN, CNRN</last_name>
      <phone>215-285-2885</phone>
      <email>frangoss@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James Schuster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Walsh, RN</last_name>
      <phone>412-647-8569</phone>
    </contact>
    <contact_backup>
      <last_name>Kelli Davis, RN, MSN</last_name>
      <phone>(412) 235-1316</phone>
    </contact_backup>
    <investigator>
      <last_name>Jan Drappatz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heinrich Elinzano, MD</last_name>
      <phone>401-444-4673</phone>
    </contact>
    <investigator>
      <last_name>Heinrich Elinzano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheree Adams</last_name>
      <phone>512-421-4183</phone>
      <email>sheree.adams@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Marlena Griffin, BSc</last_name>
      <phone>512-421-4100</phone>
      <email>marlena.griffin@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Morris D Groves, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Rivera</last_name>
      <phone>214-818-8472</phone>
      <email>Grace.Rivera@BaylorHealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Valerie Clark</last_name>
      <phone>214-820-6168</phone>
    </contact_backup>
    <investigator>
      <last_name>Karen Fink, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nitin Chandramouli, MD</last_name>
      <phone>801-269-0231</phone>
    </contact>
    <contact_backup>
      <last_name>Johnny Walker</last_name>
      <phone>801-281-6864</phone>
      <email>research@utahcancer.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nitin Chandramouli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fereshteh Assadian, RN</last_name>
      <phone>206-288-6693</phone>
      <email>fassadia@uw.edu</email>
    </contact>
    <contact_backup>
      <phone>206-685-5597</phone>
    </contact_backup>
    <investigator>
      <last_name>Maciej Mrugala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 24, 2013</lastchanged_date>
  <firstreceived_date>December 21, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFRvIII</keyword>
  <keyword>Glioblastoma</keyword>
  <keyword>Rindopepimut</keyword>
  <keyword>CDX-110</keyword>
  <keyword>Small cell</keyword>
  <keyword>Giant cell</keyword>
  <keyword>Brain Cancer</keyword>
  <keyword>Brain Tumor</keyword>
  <keyword>Gliosarcoma</keyword>
  <keyword>oligodendroglial</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>chemoradiation</keyword>
  <keyword>Tumor</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Returned</keyword>
  <keyword>Recurrent</keyword>
  <keyword>EGFR variant III</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
